FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to using Mycobacterium w for treating desmocollin-3 expressing cancer. Mycobacterium w is administered into mammals suffering desmocollin-3 expressing cancers.
EFFECT: administering Mycobacterium w leads to cancer control and statistically adequate increase of a survival rate, and a prolonged remission of more than 15 months Mycobacterium w is also applicable as necessary together with another therapeutic agent (therapeutic agents) and/or modalities.
6 cl, 3 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | 2016 |
|
RU2796903C2 |
| MONOCLONAL ANTIBODIES FOR TUMOUR TREATMENT | 2009 |
|
RU2531758C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| TREATING PANCREATIC CANCER AND NON-SMALL CELL LUNG CANCER WITH ATR INHIBITORS | 2012 |
|
RU2648507C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
